MRC1 and neoplasm: A non-statistically-significant trend toward increased TMB at recurrence was observed in the 10 TMZ-treated patients, but no case was described as having acquired post-treatment MMR protein loss or corresponding MMR gene mutation, including one patient with DHG whose tumor had H3-3A G34V (p.G35V) mutation.